Dr. Nardi received her M.D. from the University of Genoa, Italy, where she completed a fellowship in hematology/oncology. She pursued postdoctoral research on tyrosine kinase inhibitor resistance in chronic myeloid leukemia at Boston Children's Hospital. This led her to a career in molecular diagnostics. Dr. Nardi completed an anatomic pathology residency and a hematopathology fellowship at Massachusetts General Hospital, followed by a Harvard-wide Molecular Genetic Pathology fellowship. She is now an associate professor of Pathology at HMS and the Associate Director of Hematological Molecular Pathology at Mass General Brigham, focusing on molecular assays for hematological malignancies and rapid detection of gene fusions in leukemias and sarcomas. Her research aims to uncover genetic driver mutations for therapeutic intervention. Dr. Nardi is a nationally and internationally known and respected hematopathologist. She serves on the editorial boards of several journals in the fields of hematopathology and molecular diagnostic pathology and has contributed to diagnostic and clinical care guidelines published by the WHO, National Comprehensive Cancer Network (NCCN), and NIH.